Impax Laboratories Inc  

(Public, NASDAQ:IPXL)   Watch this stock  
Find more results for IPXL
28.84
+0.83 (2.96%)
After Hours: 28.84 0.00 (0.00%)
Jun 28, 4:39PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 28.39 - 29.31
52 week 27.62 - 51.42
Open 28.43
Vol / Avg. 579,652.00/655,358.00
Mkt cap 2.04B
P/E 60.15
Div/yield     -
EPS 0.48
Shares 73.81M
Beta 1.20
Inst. own 91%
Aug 8, 2016
Q2 2016 Impax Laboratories Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 21, 2016
Impax Signs Definitive Agreements to Acquire Generic Products
Jun 8, 2016
Impax Laboratories Inc at Goldman Sachs Global Healthcare Conference - Webcast
May 17, 2016
Impax Laboratories Inc Annual Shareholders Meeting
May 11, 2016
Impax Laboratories Inc Annual Shareholders Meeting (Estimated)
May 10, 2016
Impax Laboratories Inc at Bank of America Merrill Lynch Health Care Conference
May 10, 2016
Q1 2016 Impax Laboratories Inc Earnings Release
May 10, 2016
Q1 2016 Impax Laboratories Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -4.62% 4.53%
Operating margin -4.48% 6.12%
EBITD margin - 18.18%
Return on average assets -2.19% 2.60%
Return on average equity -3.92% 4.00%
Employees 1,290 -
CDP Score - -

Address

30831 Huntwood Ave
HAYWARD, CA 94544-7003
United States - Map
+1-510-2406000 (Phone)
+1-510-2406096 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Officers and directors

Robert L. Burr Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
G. Frederick Wilkinson President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Bryan M. Reasons Chief Financial Officer, Senior Vice President - Finance
Age: 47
Bio & Compensation  - Reuters
Michael J. Nestor President - Impax Pharmaceutical Division
Age: 62
Bio & Compensation  - Reuters
Deborah Penza Senior Vice President, Chief Compliance Officer
Bio & Compensation  - Reuters
Mark A. Schlossberg Esq. Senior Vice President, General Counsel, Corporate Secretary
Age: 54
Bio & Compensation  - Reuters
Donna Marie Hughes Senior Vice President of Human Resources
Bio & Compensation  - Reuters
Jeffrey D Nornhold Senior Vice President - Technical Operations
Age: 49
Bio & Compensation  - Reuters
Janet S. Vergis Director
Age: 51
Bio & Compensation  - Reuters
Leslie Z. Benet Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters